Quest PharmaTech Inc. (CVE:QPT – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 2250 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Stock Performance
The company has a current ratio of 0.40, a quick ratio of 0.52 and a debt-to-equity ratio of 4.35. The stock’s 50 day moving average is C$0.03 and its 200 day moving average is C$0.03. The stock has a market capitalization of C$3.38 million, a price-to-earnings ratio of 0.67 and a beta of 0.00.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.
Read More
- Five stocks we like better than Quest PharmaTech
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
